The selling is too small to read through as a bearish signal, it likely reflects routine diversification or tax planning. Monitor for any upcoming earnings or pipeline catalyst that would give these sales more context. No immediate trading action warranted.
ORKA drugs
ORKA drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Jun 16 $67.71entry
- T+1 · 5mo ago +4.68%α +5.93% · $70.88
- T+5 · 5mo ago +23.17%α +25.40% · $83.40
- T+20 · 4mo ago +29.18%α +28.98% · $87.47
- T+60 · 2mo ago +35.36%α +34.36% · $91.65
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Two insiders at Oruka Therapeutics, General Counsel Paul Quinlan and Director Carl Dambkowski, sold a combined $933K in open-market transactions over four days. While the insider cluster is selling, the total value is only ~0.02% of the company's $4.2B market cap, making the signal economically trivial. The cross-filing actuarial verdicts strongly amplify the cluster-earnings-context and cluster-insider-trades pair, but neither earnings nor other material cross-filings are present in the actual context provided, so the amplifiers fire without a substantive base event.
Key Financial Metrics
Key Facts
- Cluster comprises 2 insiders selling over 4-day window (June 11–15, 2026)
- Total open-market sales: $933K, roughly 0.02% of ORKA's $4.2B market cap
- Director Dambkowski sold 35K shares combined for ~$2.45M; General Counsel Quinlan sold 733 shares for $51K
- No earnings, offering, or material corporate event cross-filings present to provide informational context
- Institutional ownership heavy (Fidelity $365M, BlackRock $173M) with net accumulation pattern (6 adds vs 5 trims)
Financial Impact
Insider sales of $933K represent a de minimis 0.02% of market cap; no material financial impact
Risk Factors
- If future filings reveal an unannounced negative catalyst (e.g., trial failure, regulatory delay), these sales could appear prescient in hindsight
- Director Dambkowski's sales at ~$70 are near the current price; further acceleration above 0.5% of market cap would be more concerning
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-ORKA-1781563855572 |
Track record
40 reports on ORKA
7 of 10 bullish or bearish reports moved the stock their way by T+20. Best: +80.05% at T+60 after the Jun 1, 2026 report. 11 of 11 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 3/10 Entry $102.46 Now $99.24 −3.14% settles Dec 15
- Nov 16, 2026today SC 13G/A Neutral 2/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $106.15 Now $99.24 −6.51% settles Dec 15
- Nov 13, 20263d ago Insider Cluster Neutral 2/10 Entry $104.89 Now $99.24 −5.39% settles Dec 15
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 12, 20264d ago 144 Neutral 2/10 Entry $105.35 Now $99.24 −5.80% settles Dec 14
- Nov 9, 20267d ago Press Release Neutral 5/10 Entry $109.50 Now $99.24 −9.37% settles Dec 9
- Nov 2, 202614d ago Institutional Cluster Neutral 2/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Nov 2, 202614d ago 144 Neutral 3/10 Entry $99.55 Now $99.24 −0.31% settles Dec 2
- Oct 26, 202621d ago 8-K Bullish 6/10 Entry $90.33 Now $99.24 +9.86% settles Nov 23
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers